L
Luc Bilodeau
Researcher at Montreal Heart Institute
Publications - 57
Citations - 3060
Luc Bilodeau is an academic researcher from Montreal Heart Institute. The author has contributed to research in topics: Myocardial infarction & Restenosis. The author has an hindex of 26, co-authored 57 publications receiving 2953 citations. Previous affiliations of Luc Bilodeau include Université de Montréal & McGill University.
Papers
More filters
Journal ArticleDOI
Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group.
Jean-Claude Tardif,Gilles Côté,Jacques Lespérance,Martial G. Bourassa,Jean Lambert,Serge Doucet,Luc Bilodeau,Stanley Nattel,P de Guise +8 more
TL;DR: The antioxidant probucol is effective in reducing the rate of restenosis after balloon coronary angioplasty, and this study is the first to show this effect in a double-blind, randomized trial.
Journal ArticleDOI
VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial.
Duncan J. Stewart,Michael J.B. Kutryk,David Fitchett,Michael R. Freeman,Nancy Camack,Yinghua Su,Anthony Della Siega,Luc Bilodeau,Jeffrey R. Burton,Guy Proulx,Sam Radhakrishnan +10 more
TL;DR: There was no difference between the VEGF-treated and the placebo groups in the primary end point of change in myocardial perfusion from baseline to 3 or 6 months, assessed by single photon emission tomography (SPECT) imaging, although a significant reduction in the ischemic area was seen in both groups.
Journal ArticleDOI
Biocompatibility aspects of new stent technology
Olivier F. Bertrand,Rajender Sipehia,Rosaire Mongrain,Josep Rodés,Jean-Claude Tardif,Luc Bilodeau,Gilles Côté,Martial G. Bourassa +7 more
TL;DR: Stent implantation represents a major step forward since the introduction of coronary angioplasty and as indications continue to expand, better understanding of the early and late biocompatibility issues appears critical.
Journal ArticleDOI
Delivery platform for hydrophobic drugs: prodrug approach combined with self-assembled multilayers.
Benjamin Thierry,Piotr Kujawa,Cathy Tkaczyk,Francoise M. Winnik,Luc Bilodeau,Maryam Tabrizian +5 more
TL;DR: It is shown that the presence of the hydrophobic paclitaxel moieties does not prohibit the layer-by-layer construction of the multilayers and application of this delivery platform to substrates such as colloids, biomedical implants, or vascular tissues may lead to new therapeutic strategies.
Journal ArticleDOI
Nitinol versus stainless steel stents: acute thrombogenicity study in an ex vivo porcine model.
TL;DR: Along with the unique mechanical properties of nitinol, its promising haemocompatibility demonstrated in this study may promote their increasing use for both peripheral and coronary revascularization procedures.